Restricted accessCase reportFirst published online 2024-6
A 67-Year-Old Man with Grade 3 Reactive Cutaneous Capillary Endothelial Proliferation Induced by Camrelizumab First Manifested in the Oral Mucosa – A Case Report
Reactive cutaneous capillary endothelial proliferation (RCCEP) is the most common immune-related adverse event induced by camrelizumab (SHR-1210). Very rare cases have been reported in oral tissues, especially the oral mucosa. We reported a 67-year-old male with Grade 3 RCCEP. Multiple dome-shaped and bright red papules were first observed in the oral mucosa, which gradually developed on his lip, face, scalp, neck, foot, calf, abdomen and groin. The patient's symptoms gradually improved at 4 weeks after SHR-1210 discontinuation and were mostly relieved at 7 weeks after discontinuation. Our findings revealed that oral examination should be performed regularly during SHR-1210 treatment.
ZhangZLuMQinY, et al.Neoantigen: a new breakthrough in tumor immunotherapy. Front Immunol. 2021;12:672356. doi:10.3389/fimmu.2021.672356
2.
O'KaneGMLabbéCDohertyMK, et al.Monitoring and management of immune-related adverse events associated with programmed cell death protein-1 axis inhibitors in lung cancer. The Oncologist. 2017;22:70‐80. doi:10.1634/theoncologist.2016-0164
3.
HuangJXuJChenY, et al.Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2020;21:832‐842. doi:10.1016/s1470-2045(20)30110-8
4.
ZhouCChenGHuangY, et al.Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med. 2021;9(3):305‐314. doi:10.1016/s2213-2600(20)30365-9
5.
XuJShenJGuS, et al.Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase II trial. Clin Cancer Res. 2021;27(4):1003‐1011. doi:10.1158/1078-0432.Ccr-20-2571
6.
YuQWangWX. Camrelizumab (SHR-1210) leading to reactive capillary hemangioma in the gingiva: a case report. World J Clin Cases. 2020;8(3):624‐629. doi:10.12998/wjcc.v8.i3.624
7.
TengYGuoRSunJ, et al.Reactive capillary hemangiomas induced by camrelizumab (SHR-1210), an anti-PD-1 agent. Acta Oncol. 2019;58(3):388‐389. doi:10.1080/0284186x.2019.1567935
8.
WangFQinSSunX, et al.Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial. J Hematol Oncol. 2020;13(1):47. doi:10.1186/s13045-020-00886-2
9.
GagnierJJKienleGAltmanDG, et al.The CARE guidelines: consensus-based clinical case reporting guideline development. Headache. 2013;53(10):1541‐1547. doi:10.1111/head.12246
10.
SangroBSarobePHervás-StubbsS, et al.Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(8):525‐543. doi:10.1038/s41575-021-00438-0
11.
PostowMASidlowRHellmannMD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158‐168. doi:10.1056/NEJMra1703481
12.
ChenLFliesDB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227‐242. doi:10.1038/nri3405
13.
HeXXuC. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020;30(8):660‐669. doi:10.1038/s41422-020-0343-4
14.
HwangSJCarlosGWakadeD, et al.Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol. 2016;74(3):455‐461.e451. doi:10.1016/j.jaad.2015.10.029
15.
QinSRenZMengZ, et al.Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 2020;21(4):571‐580. doi:10.1016/s1470-2045(20)30011-5
16.
FangWYangYMaY, et al.Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 2018;19(10):1338‐1350. doi:10.1016/s1470-2045(18)30495-9
17.
MoHHuangJXuJ, et al.Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study. Br J Cancer. 2018;119(5):538‐545. doi:10.1038/s41416-018-0100-3
18.
FinlayWJJColemanJEEdwardsJS, et al.Anti-PD1 ‘SHR-1210’ aberrantly targets pro-angiogenic receptors and this polyspecificity can be ablated by paratope refinement. MAbs. 2019;11(1):26‐44. doi:10.1080/19420862.2018.1550321
19.
LertpimonchaiARattanasiriSArj-Ong VallibhakaraS, et al.The association between oral hygiene and periodontitis: a systematic review and meta-analysis. Int Dent J. 2017;67(6):332‐343. doi:10.1111/idj.12317
20.
D’AndréaGLassalleSGuevaraN, et al.From biomarkers to therapeutic targets: the promise of PD-L1 in thyroid autoimmunity and cancer. Theranostics. 2021;11(3):1310‐1325. doi:10.7150/thno.50333
21.
EsfahaniKElkriefACalabreseC, et al.Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol. 2020;17(8):504‐515. doi:10.1038/s41571-020-0352-8
22.
WuPSXiongDFengYB, et al.Case report: a case of acute mastitis associated with reactive cutaneous capillary endothelial proliferation after camrelizumab treatment: a new immune-related adverse event. Front Immunol. 2022;13:939873. doi:10.3389/fimmu.2022.939873
